

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	434	(514/245).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/09/25 13:21
S1	696	(544/198).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/20 14:32
S2	438	(544/207).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:28
S3	26	christopher.inv. and Penney.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:28
S4	35	boulos.inv. and Zacharie.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:29
S5	7	Shaun.inv. and Abbott.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:29
S6	5	Jean-Francois.inv. and Bienvenu. inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:30
S7	41	S3 or S4 or S5 or S6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:30
S8	0	cipoli.inv. and triazine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/20 14:34
S9	84	cipolli.inv. and triazine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/20 14:35
S10	6	((("5606055") or ("4963461") or ("5629382"))).PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/09/25 09:49

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
L1	434	(514/245).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/09/25 13:21
S1	696	(544/198).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/20 14:32
S2	438	(544/207).CCLS.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:28
S3	26	christopher.inv. and Penney.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:28
S4	35	boulos.inv. and Zacharie.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:29
S5	7	Shaun.inv. and Abbott.inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:29
S6	5	Jean-Francois.inv. and Bienvenu. inv.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:30
S7	41	S3 or S4 or S5 or S6	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/09 16:30
S8	0	cipoli.inv. and triazine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/20 14:34
S9	84	cipolli.inv. and triazine	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/08/20 14:35
S10	6	((("5606055") or ("4963461") or ("5629382"))).PN.	US-PGPUB; USPAT; EPO; JPO; DERWENT	OR	OFF	2007/09/25 09:49

CORRECTION

Incorrect Statements on Funding/Support and Role of the Sponsors and Incorrect and Incomplete Financial Disclosures: In the Review entitled "Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials" published in the May 17, 2006, issue of *JAMA* (2006; 295:2275-2285), the following errors appeared:

After this issue was printed and mailed, *JAMA* was informed by the authors that information reported on page 2284 of the article was incorrect.

The Funding/Support statement should have read "This study was supported by the Mayo Foundation. Additional data were provided by Abbott and Centocor. Data provided by Abbott were subject to a confidentiality agreement."

The Role of the Sponsors statement should have read "Abbott and Centocor did not have any role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation or approval of the manuscript. The manuscript was sent to Abbott for review prior to submission for publication."

The Financial Disclosures statement should have read: "Dr Bongartz reported that he has given lectures for Abbott as part of seminars for study nurses and received honorarium in the form of a medical textbook for the Internal Medicine library; he received an educational grant from Amgen in February 2006 to perform the same type of analysis of harmful events under anti-TNF treatment for etanercept; and he received the 2005 Fellow's Award of the American College of Rheumatology, which was supported by Amgen."

Dr Matteson reported that he has been a paid consultant for Centocor for work unrelated to this study and has been working with Wyeth and Amgen to perform a similar analysis for etanercept; he has been an Investigator for the American College of Rheumatology, Amgen, Asta, Biogen-IDEC, Burroughs-Wellcome, Centocor, Cypress, Endocyte Inc, Genentech, Hoffmann-LaRoche, Human Genome Sciences, Immunex, Protein Design Laboratories, Natestech, Pharmacia & Upjohn, Schering, Wyeth, and Xoma Corp; he has received grant support from Amgen, Aventis, Centocor/Johnson & Johnson, Genentech, Immunex, Mayo Foundation, Novartis, and the National Institutes of Health; and he has been a consultant for Amgen, BoneandJoint.org, Burroughs-Wellcome, Centocor, Regeneron, Takeda, Upjohn, Watermark Research, and the Vasculitis Foundation."

This correction is being published online on May 16, 2006. Because of the nature and extensiveness of this incorrect and incomplete reporting, *JAMA* has requested that the Mayo Clinic College of Medicine conduct an investigation. *JAMA* will publish another correction or clarification once the results of that investigation become available.

LETTERS

Table. Annual Number of Laparoscopic Cases

Procedure	Years Since Introduction														
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15
Cholecystectomy	16 247	93 464	270 991	363 161	354 565	348 323	331 076	333 600	327 092	316 733	319 793	346 157	351 736	360 844	358 069
Fundoplication	19	184	1613	5299	11 245	13 111	15 802	18 399	23 993	24 761	24 188	18 981	19 042		
Hysterectomy	4838	6181	13 102	38 929	44 852	41 401	42 335	48 578	68 455	60 805	60 733	64 639	69 659	71 977	76 033
Nephrectomy indication															
Cancer	35	236	215	199	283	308	563	532	701	1226	1968	4221	5093		
Benign disease	452	454	573	614	767	898	1261	1055	1947	1662	1896	2823	3388		
Donor	11	4	19	21	40	154	473	449	510	1589	1305	1648	1789		

Critical revision of the manuscript for important intellectual content: Miller, Dunn, Wei, Hollenbeck.

Statistical analysis: Dunn.

Obtained funding: Hollenbeck.

Administrative, technical, or material support: Hollenbeck.

Study supervision: Wei, Hollenbeck.

Financial disclosures: None reported.

Funding/Support: Dr Miller is supported by grant NIH-1-T-32 DKO7782 (DCM), a clinical research training grant, from the National Institute of Diabetes and Digestive and Kidney Diseases.

Role of the Sponsor: The study sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript.

1. Best S, Ercole B, Lee C, Fallon E, Skenazy J, Monga M. Minimally invasive therapy for renal cell carcinoma: is there a new community standard? *Urology*. 2004;64:22-25.
2. Dunn MD, Portis AJ, Shalhav AL, et al. Laparoscopic versus open radical nephrectomy: a 9-year experience. *J Urol*. 2000;164:1153-1159.
3. Huynh PN, Hollander JB. Trends toward laparoscopic nephrectomy at a community hospital. *J Urol*. 2005;173:547-551.
4. Agency for Healthcare Research and Quality. *Healthcare Cost and Utilization Project: Nationwide Inpatient Sample*. Rockville, Md: Agency for Healthcare Research and Quality; 2005.
5. Rudich SM, Marcovich R, Magee JC, et al. Hand-assisted laparoscopic donor nephrectomy: comparable donor/recipient outcomes, costs, and decreased convalescence as compared to open donor nephrectomy. *Transplant Proc*. 2001;33:1106-1107.
6. Johnson N, Barlow D, Lethaby A, Tavender E, Curr L, Garry R. Methods of hysterectomy: systematic review and meta-analysis of randomised controlled trials. *BMJ*. 2005;330:1478-1485.
7. Miller DC, Taub DA, Dunn RL, Wei JT, Hollenbeck BK. Laparoscopy for renal cell carcinoma: diffusion versus regionalization? *J Urol*. In press.
8. Escarce JJ. Externalities in hospitals and physician adoption of a new surgical technology: an exploratory analysis. *J Health Econ*. 1996;15:715-734.

CORRECTIONS

Incorrect Unit of Measure: In the Original Contribution entitled "Effect of 6-Month Calorie Restriction on Biomarkers of Longevity, Metabolic Adaptation, and Oxidative Stress in Overweight Individuals: A Randomized Controlled Trial" published in the April 5, 2006, issue of *JAMA* (2006;295:1539-1548), an incorrect unit of measure was given for dehydroepiandrosterone sulfate (DHEAS). On page 1543 (Table 1) and page 1544 (Figure 3), the unit of measure for DHEAS should be $\mu\text{g/dL}$ (not ng/mL).

Error in Byline: In the Original Contribution entitled "Incidence and Prognostic Implications of Stable Angina Pectoris Among Women and Men" published in the March 22/29, 2006, issue of *JAMA* (2006;295:1404-1411), the byline contained an incorrect academic degree. Alison McCallum should have been listed as having an MBChB, FFPH.

Incorrect Data: In the Original Contribution entitled "Frequency and Effect of Adjuvant Radiation Therapy Among Women With Stage I Endometrial Adenocarcinoma" published in the January 25, 2006, issue of *JAMA* (2006;295:389-397), incorrect data were reported in the "Results" section of the article. On page 391, the sentence "Within the RT cohort, 2551 patients (62.5%) had external beam radiation, 732 (17.9%) had vaginal brachytherapy, and 1078 (26.4%) received a combination of external beam radiation with vaginal brachytherapy" should have read "Within the RT cohort, 2378 patients (58.3%) received external beam radiation, 962 (23.6%) received external beam and brachytherapy radiation, 654 (16.0%) received brachytherapy radiation alone, and for 86 (2.1%) the radiation modality was not specified." The authors verified that this error did not have an impact on the data set or subsequent statistical analyses.

Incorrect Statements on Funding/Support and Role of the Sponsors and Incorrect and Incomplete Financial Disclosures: In the Review entitled "Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies: Systematic Review and Meta-analysis of Rare Harmful Effects in Randomized Controlled Trials" published in the May 17, 2006, issue of *JAMA* (2006;295:2275-2285), the following errors appeared:

After this issue was printed and mailed, *JAMA* was informed by the authors that information reported on page 2284 of the article was incorrect.

The Funding/Support statement should have read "This study was supported by the Mayo Foundation. Additional data were provided by Abbott and Centocor. Data provided by Abbott were subject to a confidentiality agreement."

The Role of the Sponsors statement should have read "Abbott and Centocor did not have any role in the design and conduct of the study; the collection, management, analysis, and interpretation of the data; or the preparation or approval of the manuscript. The manuscript was sent to Abbott for review prior to submission for publication."

The Financial Disclosures statement should have read: "Dr Bongartz reported that he has given lectures for Abbott as part of seminars for study nurses and received honorarium in the form of a medical textbook for the Internal Medicine library; he received an educational grant from Amgen in February 2006 to perform the same type of analysis of harmful events under anti-TNF treatment for etanercept; and he received the 2005 Fellow's Award of the American College of Rheumatology, which was supported by Amgen."

Dr Matteson reported that he has been a paid consultant for Centocor for work unrelated to this study and has been working with Wyeth and Amgen to perform a similar analysis for etanercept; he has been an Investigator for the American College of Rheumatology, Amgen, Asta, Biogen-IDEc, Burroughs-Wellcome, Centocor, Cypress, Endocyte Inc, Genentech, Hoffmann-LaRoche, Human Genome Sciences, Immunex, Protein Design Laboratories, Nastech, Pharmacia & Upjohn, Schering, Wyeth, and Xoma Corp; he has received grant support from Amgen, Aventis, Centocor/Johnson & Johnson, Genentech, Immunex, Mayo Foundation, Novartis, and the National Institutes of Health; and he has been a consultant for Amgen, BoneandJoint.org, Burroughs-Wellcome, Centocor, Regeneron, Takeda, Upjohn, Watermark Research, and the Vasculitis Foundation."

This correction was published online on May 16, 2006. Because of the nature and extensiveness of this incorrect and incomplete reporting, *JAMA* has requested that the Mayo Clinic College of Medicine conduct an investigation. *JAMA* will publish another correction or clarification once the results of that investigation become available.